TLRs 7 and 8 are located in endosomal membranes rather than on the cell surface. This endosomal location is functionally appropriate because:
AThe low pH of the endosome stabilizes RNA-receptor binding and enhances signaling
BSingle-stranded viral RNA is only exposed after a virus is internalized and its protein coat is stripped in the endosome
CCell surface location would make TLRs 7 and 8 vulnerable to cleavage by extracellular proteases
DEndosomal TLRs require co-stimulation from surface TLRs before they can initiate signaling
The location of a TLR must match where its ligand is encountered. Single-stranded RNA from viruses (TLR7/8) and double-stranded RNA from viral replication (TLR3) are not accessible on the cell surface — they are hidden inside viral particles until the virus is internalized and degraded in the endosome. Placing these TLRs in the endosomal membrane positions the receptor exactly where the ligand becomes detectable. This also reduces the risk of erroneously detecting self RNA circulating extracellularly.
Question 2 Multiple Choice
A patient with a homozygous loss-of-function mutation in MyD88 presents with recurrent, severe bacterial infections. The most likely immunological explanation is:
AInability to produce type I interferons, leaving the patient vulnerable to viral infections
BFailure of most TLRs to activate NF-κB, eliminating the pro-inflammatory cytokine response needed to fight pyogenic bacteria
CLoss of complement activation, preventing opsonization of bacteria
DSelective impairment of antifungal responses, because MyD88 is specifically required for fungal PAMP signaling
MyD88 is the adaptor protein used by most TLRs (all except TLR3, and partially TLR4) to activate NF-κB. NF-κB drives expression of TNF-α, IL-1, IL-6, and other pro-inflammatory cytokines that recruit neutrophils and macrophages to sites of bacterial infection. Without MyD88, this response is severely impaired, leaving patients unable to mount the initial inflammatory response to pyogenic bacteria. Type I interferon production via TRIF (used by TLR3 and TLR4) is preserved, which is why viral immunity is less affected.
Question 3 True / False
The MyD88-dependent and TRIF-dependent TLR signaling pathways both ultimately activate NF-κB, which drives production of both pro-inflammatory cytokines and type I interferons.
TTrue
FFalse
Answer: False
The two pathways activate distinct transcription factors with distinct outputs. MyD88 activates NF-κB, driving pro-inflammatory cytokines (TNF-α, IL-1, IL-6). TRIF activates IRF3 and IRF7, driving type I interferons (IFN-α/β) — the antiviral cytokines that induce an antiviral state in neighboring cells. These are not the same response: one is inflammatory (recruiting immune cells), the other is antiviral (blocking viral replication). TLR4 is unique in activating both pathways, which is why LPS triggers both inflammation and an interferon response.
Question 4 True / False
TLR4 is uniquely potent as an immune stimulus in Gram-negative sepsis partly because it is the only TLR that activates both the MyD88 and TRIF signaling pathways simultaneously.
TTrue
FFalse
Answer: True
Most TLRs use exclusively either MyD88 (inflammatory cytokines via NF-κB) or TRIF (type I interferons via IRF3). TLR4 is exceptional: upon LPS binding, it recruits both adaptors, activating NF-κB (inflammation) AND IRF3 (type I interferons). This dual activation amplifies the immune response synergistically. In sepsis, massive LPS exposure triggers this combined response system-wide, producing the cytokine storm that characterizes septic shock. Understanding TLR4's dual pathway also explains why it is a major drug target for modulating the sepsis response.
Question 5 Short Answer
Why does the division of TLRs between cell-surface and endosomal locations represent an elegant design for distinguishing bacterial from viral threats?
Think about your answer, then reveal below.
Model answer: Bacterial threats are typically extracellular — their PAMPs (LPS, peptidoglycan, flagellin) are exposed on the bacterial surface and accessible to receptors on the outer face of the cell. Cell-surface TLRs (TLR1, 2, 4, 5, 6) are positioned to detect exactly these extracellular structures. Viral threats are initially invisible: intact viral particles don't expose their nucleic acid contents to the outside world. Only after endocytosis and vesicle acidification are viral proteins stripped and nucleic acids exposed. Endosomal TLRs (TLR3, 7, 8, 9) are positioned inside the cell precisely where and when viral nucleic acids become detectable.
This compartmentalization also reduces autoimmunity risk. Self DNA and RNA are present throughout the cytoplasm and extracellular space. Placing nucleic acid-sensing TLRs in endosomes means they are less likely to encounter self nucleic acids (which are not normally routed through the endosomal pathway) and more likely to encounter pathogen-derived nucleic acids (which arrive via endocytosis of pathogens). When this system fails — as in systemic lupus erythematosus, where self DNA enters endosomes — inappropriate TLR9 activation can contribute to autoimmune pathology.